secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001213900-25-044286
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus Life Sciences Q1 2025 net loss narrows to $2.3M; revenue flat at $2.4M
-----------------------------------------------------------------------------

- Net loss $2.3M ($0.04/sh) improved from $4.3M loss YoY; operating loss narrowed to $1.0M.
- Net revenue $2.4M, down slightly from $2.5M YoY due to generic L-Glutamine competition.
- Total operating expenses fell to $3.2M from $5.0M, mainly from workforce reduction in Q4 2024.
- Cash and equivalents $1.3M at March 31, 2025, comparable to $1.4M at Dec 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390025044286/0001213900-25-044286-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390025044286/ea0242203-8k_emmaus.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-044286

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer